Abstract
Background Autism spectrum disorder (ASD) is a highly heritable neurodevelopmental disorder. Large genetically informative cohorts of individuals with ASD have led to the identification of three common genome-wide significant (GWS) risk loci to date. However, many more common genetic variants are expected to contribute to ASD risk given the high heritability. Here, we performed a genome-wide association study (GWAS) using the Simons Foundation Powering Autism Research for Knowledge (SPARK) dataset to identify additional common genetic risk factors and molecular mechanisms underlying risk for ASD.
Methods We performed an association study on 6,222 case-pseudocontrol pairs from SPARK and meta-analyzed with a previous GWAS. We integrated gene regulatory annotations to map non-coding risk variants to their regulated genes. Further, we performed a massively parallel reporter assay (MPRA) to identify causal variant(s) within a novel risk locus.
Results We identified one novel GWS locus from the SPARK GWAS. The meta-analysis identified four significant loci, including an additional novel locus. We observed significant enrichment of ASD heritability within regulatory regions of the developing cortex, indicating that disruption of gene regulation during neurodevelopment is critical for ASD risk. The MPRA identified one variant at the novel locus with strong impacts on gene regulation (rs7001340), and expression quantitative trait loci data demonstrated an association between the risk allele and decreased expression of DDHD2 (DDHD domain containing 2) in both adult and pre-natal brains.
Conclusions By integrating genetic association data with multi-omic gene regulatory annotations and experimental validation, we fine-mapped a causal risk variant and demonstrated that DDHD2 is a novel gene associated with ASD risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a grant from the Simon Foundation (SFARI[Award #: 605259], H.W and J.L.S), NIMH (R00MH113823 and DP2MH122403 to H.W. and R01MH118349, R01MH120125, R01MH121433 to J.L.S), NIGMS (DP2GM114829 to S.K.) and the NARSAD Young Investigator Award (H.W.). LMR was supported by T32 HL129982. Trans-Omics in Precision Medicine (TOPMed) program imputation panel (version Freeze5) supported by the National Heart, Lung and Blood Institute (NHLBI); see www.nhlbiwgs.org. TOPMed study investigators contributed data to the reference panel, which can be accessed through the Michigan Imputation Server; see https://imputationserver.sph.umich.edu. The panel was constructed and implemented by the TOPMed Informatics Research Center at the University of Michigan (3R01HL-117626-02S1; contract HHSN268201800002I). The TOPMed Data Coordinating Center (3R01HL-120393-02S1; contract HHSN268201800001I) provided additional data management, sample identity checks, and overall program coordination and support.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Approved researchers can obtain the SPARK population dataset described in this study (more details available at https://www.sfari.org/resource/spark/) by applying at https://base.sfari.org. TOPMed study investigators contributed data to the reference panel, which can be accessed through the Michigan Imputation Server; see https://imputationserver.sph.umich.edu. Summary statistics from the GWAS conducted here will be available upon publication.
